Want to see BOLD full AI Analyst Report?
Top Page
Boundless Bio Inc.
(NASDAQ:BOLD)
Select Model
Select Model
Rating:48Neutral
Price Target:
$3.00
▲(4.90% Upside)
Action:Reiterated
Date:08/29/26
The score is held down primarily by very weak financial performance (no revenue, sustained large losses, and heavy ongoing cash burn), which outweighs the moderately positive technical setup. Corporate events are mixed: the Serapha merger and financing can reset the company’s trajectory, but the substantial dilution/control shift and restructuring add meaningful risk. Valuation is also constrained by losses and the absence of dividend support.
Positive Factors
Positive equity base
Positive equity provides a more stable capitalization base than in earlier years and reduces immediate solvency concerns. Although the balance has contracted, the improved structure may support continued operations while the company pursues its strategic transition.
Negative Factors
No revenue and persistent losses
The absence of revenue means the company has no commercial operating base to offset research and corporate spending. Persistent large losses limit operating leverage and leave future progress dependent on clinical success, partnerships, or external financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Positive equity base
Positive equity provides a more stable capitalization base than in earlier years and reduces immediate solvency concerns. Although the balance has contracted, the improved structure may support continued operations while the company pursues its strategic transition.
Read all positive factors
Boundless Bio Inc. (BOLD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$63.92M
Dividend YieldN/A
Average Volume (3M)145.66K
Price to Earnings (P/E)―
Beta (1Y)1.19
Revenue GrowthN/A
EPS Growth1.11%
CountryUS
Employees28
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.86
Shares Outstanding22,747,986
10 Day Avg. Volume57,681
30 Day Avg. Volume145,664
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.27
Price to Sales (P/S)0.00
P/FCF Ratio-0.57
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2.4
Revenue Forecast (FY)N/A
Boundless Bio Inc. Business Overview & Revenue Model
Company Description
Boundless Bio, Inc., a clinical-stage oncology company, focuses on developing innovative cancer therapies aimed at addressing the significant unmet needs of patients with oncogene amplified tumors. Their core strategy involves targeting extrachrom...
How the Company Makes Money
Boundless Bio is a clinical-stage biotech and, as such, its revenue model is primarily not based on product sales. null...
Boundless Bio Inc. Financial Statement Overview
Summary
Income Statement
6
Very Negative
Balance Sheet
42
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -901.00K | -1.25M | -1.09M | 0.00 | 0.00 | 0.00 |
| EBITDA | -58.63M | -56.95M | -64.28M | -48.48M | -44.96M | -24.53M |
| Net Income | -64.01M | -58.20M | -65.36M | -49.43M | -45.90M | -25.21M |
Balance Sheet | ||||||
| Total Assets | 73.74M | 157.06M | 206.41M | 129.89M | 76.83M | 113.72M |
| Cash, Cash Equivalents and Short-Term Investments | 72.63M | 107.58M | 152.11M | 120.75M | 66.72M | 73.03M |
| Total Debt | 0.00 | 49.03M | 47.63M | 2.19M | 5.18M | 377.00K |
| Total Liabilities | 7.77M | 58.41M | 55.77M | 256.98M | 158.53M | 151.91M |
| Stockholders Equity | 65.98M | 98.65M | 150.64M | -127.08M | -81.70M | -38.19M |
Cash Flow | ||||||
| Free Cash Flow | -56.73M | -47.21M | -63.38M | -47.49M | -40.66M | -25.28M |
| Operating Cash Flow | -56.25M | -46.66M | -60.84M | -46.85M | -39.60M | -23.25M |
| Investing Cash Flow | 61.11M | 37.80M | -26.10M | -38.26M | 16.13M | -59.28M |
| Financing Cash Flow | 97.00K | 141.00K | 89.82M | 97.90M | 126.00K | 105.53M |
Boundless Bio Inc. Technical Analysis
Neutral
2.86
Price Trends
2.72
Positive
2.22
Positive
1.71
Positive
Market Momentum
0.02
Positive
50.91
Neutral
27.78
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BOLD, the sentiment is Neutral. The current price of 2.86 is below the 20-day moving average (MA) of 2.87, above the 50-day MA of 2.72, and above the 200-day MA of 1.71, indicating a neutral trend. The MACD of 0.02 indicates Positive momentum. The RSI at 50.91 is Neutral, neither overbought nor oversold. The STOCH value of 27.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BOLD.
Boundless Bio Inc. Risk Analysis
Boundless Bio Inc. disclosed 99 risk factors in its most recent earnings report. Boundless Bio Inc. reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
Boundless Bio and Serapha may mutually agree to waive the Nasdaq listing condition under the Merger Agreement, and if such condition is waived, the Combined Company's stock may not be listed on Nasdaq following completion of the Merger. Q2, 2026
2.
The Exchange Ratio for the Merger will not change or otherwise be adjusted based on the market price of Boundless Bio Common Stock. Q2, 2026
3.
The issuance of Boundless Bio Common Stock, including the shares of Boundless Bio Common Stock issued in exchange for shares of Serapha Common Stock issued in the Serapha Pre-Closing Financing, to Serapha stockholders pursuant to the Merger Agreement and the resulting change in control from the Merger, and the Nasdaq Reverse Split, must be approved by Boundless Bio stockholders, and the Merger Agreement and transactions contemplated thereby must be approved by the Serapha stockholders. Failure to obtain these approvals would prevent the closing of the Merger. Q2, 2026
Boundless Bio Inc. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
48 Neutral | $63.92M | -0.98 | -70.89% | ― | ― | 1.11% | |
48 Neutral | $235.07M | -1.50 | -90.30% | ― | ― | 48.20% | |
43 Neutral | $8.62M | -0.44 | -160.28% | ― | -84.26% | 14.73% | |
41 Neutral | $32.72M | -0.72 | -160.72% | ― | 893.01% | 41.74% | |
27 Underperform | $13.33M | -0.44 | 144.63% | ― | -23.95% | 30.12% |
* General Sector Average
BOLD
Boundless Bio Inc.
2.81
1.68
148.67%
PLUR
Pluri
1.08
-3.63
-77.07%
CLGN
Collplant Holdings
4.56
-20.35
-81.70%
ALXO
ALX Oncology Holdings
1.70
0.43
33.86%
ALGS
Aligos Therapeutics
5.24
-4.29
-45.02%
Boundless Bio Inc. Corporate Events
Business Operations and StrategyM&A Transactions
Boundless Bio Amends Merger Agreement with Serapha Bio
Positive
Aug 28, 2026
On June 22, 2026, Boundless Bio, Inc. agreed to merge its wholly owned subsidiary Boulder Merger Sub Corp. into Serapha Bio, Inc., with Serapha to become a wholly owned subsidiary of Boundless Bio, and on August 28, 2026, the parties executed an a...
Business Operations and StrategyExecutive/Board ChangesDividendsM&A TransactionsPrivate Placements and Financing
Boundless Bio to Merge with Serapha Bio, Restructure Operations
Negative
Jun 23, 2026
On June 22, 2026, Boundless Bio agreed to merge with privately held Serapha Bio in an all-stock transaction that will leave Serapha equityholders owning about 96% of the combined company, which will operate as Serapha Bio and list on Nasdaq under ...
Executive/Board ChangesShareholder Meetings
Boundless Bio Shareholders Back Directors and Auditor Appointments
Positive
Jun 17, 2026
At its annual meeting of stockholders held on June 15, 2026, Boundless Bio, Inc. reported that stockholders elected James Christensen, Ph.D., and Jennifer Lew as Class II directors, each to serve until the company’s 2029 annual meeting and u...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.